PMID- 9690943
OWN - NLM
STAT- MEDLINE
DCOM- 19981006
LR  - 20201215
IS  - 0306-5251 (Print)
IS  - 1365-2125 (Electronic)
IS  - 0306-5251 (Linking)
VI  - 46
IP  - 1
DP  - 1998 Jul
TI  - Pharmacokinetics of recombinant human interleukin-2 in advanced renal cell 
      carcinoma patients following subcutaneous application.
PG  - 5-10
AB  - AIMS: The aim of the study was to investigate the pharmacokinetics of recombinant 
      human interleukin-2 (rhIL-2) in patients with metastatic renal cell carcinoma 
      following different subcutaneous (s.c.) administration regimens. METHODS: RhIL-2 
      was administered subcutaneously to 10 patients according to two different dosing 
      regimens: group A received 20 x 10(6) IU m(-2) once daily and group B 10 x 10(6) 
      IU m(-2) twice daily (every 12 h). Additionally, in all patients the influence of 
      soluble interleukin-2 receptor (sIL-2R) on the pharmacokinetics of rhIL-2 was 
      investigated. RESULTS: The mean area under the serum concentration-time curve to 
      24 h (AUC(0,24 h)) was 627 IU ml(-1) h in treatment group A and 1130 IU ml(-1) h 
      (P=0.029) in treatment group B. In both study groups Cmax and AUC(0,12 h) were 
      not significantly different. Seventy-two hours after the beginning of s.c. rhIL-2 
      therapy the sIL-2R increased significantly (P=0.016), and sIL-2R levels over 1200 
      pmol l(-1) seemed to reduce the AUC. CONCLUSIONS: In patients with metastatic 
      renal cell cancer administration of 20 x 10(6) IU m(-2) of rhIL-2 s.c. in two 
      daily doses (10 x 10(6) IU m(-2) every 12 h) provides better bioavailability and 
      is preferable to the single dose administration.
FAU - Kirchner, G I
AU  - Kirchner GI
AD  - Institute for General Pharmacology, Medizinische Hochschule Hannover, Germany.
FAU - Franzke, A
AU  - Franzke A
FAU - Buer, J
AU  - Buer J
FAU - Beil, W
AU  - Beil W
FAU - Probst-Kepper, M
AU  - Probst-Kepper M
FAU - Wittke, F
AU  - Wittke F
FAU - Overmann, K
AU  - Overmann K
FAU - Lassmann, S
AU  - Lassmann S
FAU - Hoffmann, R
AU  - Hoffmann R
FAU - Kirchner, H
AU  - Kirchner H
FAU - Ganser, A
AU  - Ganser A
FAU - Atzpodien, J
AU  - Atzpodien J
LA  - eng
PT  - Journal Article
PL  - England
TA  - Br J Clin Pharmacol
JT  - British journal of clinical pharmacology
JID - 7503323
RN  - 0 (Interleukin-2)
RN  - 0 (Recombinant Proteins)
SB  - IM
MH  - Aged
MH  - Biological Availability
MH  - Carcinoma, Renal Cell/metabolism/pathology/*therapy
MH  - Drug Administration Schedule
MH  - Female
MH  - Humans
MH  - Injections, Subcutaneous
MH  - Interleukin-2/administration & dosage/*pharmacokinetics
MH  - Kidney Neoplasms/metabolism/pathology/*therapy
MH  - Male
MH  - Middle Aged
MH  - Recombinant Proteins/administration & dosage/pharmacokinetics
PMC - PMC1873983
EDAT- 1998/08/05 00:00
MHDA- 1998/08/05 00:01
PMCR- 1999/01/01
CRDT- 1998/08/05 00:00
PHST- 1998/08/05 00:00 [pubmed]
PHST- 1998/08/05 00:01 [medline]
PHST- 1998/08/05 00:00 [entrez]
PHST- 1999/01/01 00:00 [pmc-release]
AID - 10.1046/j.1365-2125.1998.00036.x [doi]
PST - ppublish
SO  - Br J Clin Pharmacol. 1998 Jul;46(1):5-10. doi: 10.1046/j.1365-2125.1998.00036.x.